SCHEMBL3010553

SCHEMBL3010553

Cc1cc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Br)cc4)CC3)n2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
USP2 O75604 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
NOD2 Q9HC29 1/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 3/20 0.40
GAA P10253 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013533 0.93 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3018874 0.91 SMN1; SMN2 (0.47) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL3019344 0.90 SMN1; SMN2 (0.44) SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3011003 0.90 POLB (0.46) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL3007181 0.90 ALDH1A1 (0.58) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL3010900 0.89 GBA1 (0.43) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL3013298 0.89 SMN1; SMN2 (0.46) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL3010683 0.88 HSD11B1 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3005822 0.87 HDAC3 (0.45) SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3010162 0.87 SMN1; SMN2 (0.46) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885KDM4E 4398/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.